Stocks Health care DFTX
NASDAQ · Health careDefinium Therapeutics, Inc. (DFTX)
It posted a net loss of $337.5M. At September 30, 2026 it held $241.2M in cash against $36.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Definium Therapeutics, Inc.
- Net worth
- Definium Therapeutics, Inc. has a market value (market cap) of $4.6B at the latest share price, and shareholders' equity of $968M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $131.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Definium Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Definium Therapeutics, Inc. does
Definium Therapeutics, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker DFTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$183.8M | -$2.06 | n/a |
| 2024 | n/a | -$108.7M | -$1.54 | n/a |
| 2023 | n/a | -$95.7M | -$2.44 | n/a |
| 2022 | n/a | -$56.8M | -$1.84 | n/a |
| 2021 | n/a | -$93M | -$3.40 | n/a |
| 2021 | n/a | -$33.9M | -$1.92 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Definium Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 5, 2026Passive stake (5% or more) SCHEDULE 13G
- September 14, 2026
- September 8, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 6, 2026
- August 6, 2026
Insider trades
What the people running Definium Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 25, 2026 | Roberts BrandiChief Financial Officer | Soldpre-planned (10b5-1) | 3,377 | $123.5K |
| September 25, 2026 | Sullivan MarkChief Legal Officer | Soldpre-planned (10b5-1) | 14,051 | $513.8K |
| September 25, 2026 | Wiley Matthew T.Chief Commercial Officer | Soldpre-planned (10b5-1) | 3,097 | $113.3K |
| September 25, 2026 | Barrow RobertChief Executive Officer, Director | Soldpre-planned (10b5-1) | 31,550 | $1.2M |
| September 25, 2026 | Karlin DanielChief Medical Officer, Director | Soldpre-planned (10b5-1) | 10,853 | $396.9K |
| September 18, 2026 | Vallone Carol ADirector | Exercised options | 1,086 | $38.6K |
| September 18, 2026 | Krebs AndreasDirector | Exercised options | 1,629 | $57.9K |
| September 14, 2026 | Barrow RobertChief Executive Officer, Director | Received as pay | 750,000 | - |
Who owns DFTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 6.5% | November 5, 2026 |
| Driehaus Capital Management LLC13G, passive | 5.36% | August 14, 2026 |
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 5.08% | February 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 360 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 11,232,834 | +2,752,604 |
| Avoro Capital Advisors LLC | 7,188,888 | +2,188,888 |
| Driehaus Capital Management LLC | 6,845,276 | +933,387 |
| Jupiter Topco LLC | 5,615,645 | new |
| Capital World Investors | 5,367,723 | new |
| Fmr LLC | 4,752,921 | +2,943,311 |
| Geode Capital Management, LLC | 3,644,813 | +1,149,414 |
| State Street Corp | 3,065,390 | +593,517 |
| Capital International Investors | 2,963,410 | new |
| Octagon Capital Advisors LP | 2,950,000 | +510,000 |
| Wellington Management Group Llp | 2,949,734 | +1,644,985 |
| Deep Track Capital, LP | 2,750,000 | -250,000 |
| Commodore Capital LP | 2,000,000 | 0 |
| Goldman Sachs Group Inc | 1,800,852 | +125,441 |
| Citadel Advisors LLC | 1,688,587 | +355,145 |
| Vanguard Portfolio Management LLC | 1,648,426 | +775,761 |
| RA Capital Management, L.P. | 1,500,000 | new |
| Vanguard Capital Management LLC | 1,486,454 | +389,476 |
| Siren, L.L.C. | 1,419,493 | +500,000 |
| Marshall Wace, Llp | 1,298,946 | +98,121 |
Insiders
11 insiders reported holding 4,369,459 shares in total, about $149.4M at the last price.
| Holder | Shares |
|---|---|
| Barrow RobertChief Executive Officer, Director | 2,213,090 |
| Karlin DanielChief Medical Officer, Director | 792,846 |
| Sullivan MarkChief Legal Officer | 494,228 |
| Roberts BrandiChief Financial Officer | 394,528 |
| Wiley Matthew T.Chief Commercial Officer | 359,036 |
| Bruhn Suzanne LouiseDirector | 24,289 |
| Crystal RogerDirector | 24,289 |
| Vallone Carol ADirector | 22,296 |
| Krebs AndreasDirector | 21,402 |
| Gryska David WDirector | 19,900 |
Questions about DFTX
What does Definium Therapeutics, Inc. do?
Definium Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DFTX. Its shares trade on NASDAQ under the ticker DFTX.
What is Definium Therapeutics, Inc.'s net worth?
Definium Therapeutics, Inc. has a market value (market cap) of $4.6B at the latest share price, and shareholders' equity of $968M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Definium Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $337.5M.
When did Definium Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Definium Therapeutics, Inc.'s next earnings report?
Definium Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DFTX with
Follow DFTX
Get an email when Definium Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Definium Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.